CD45 congenic bone marrow transplantation: evidence for T cell-mediated immunity
- PMID: 15536194
- DOI: 10.1634/stemcells.22-6-1039
CD45 congenic bone marrow transplantation: evidence for T cell-mediated immunity
Abstract
CD45 congenic mice have been used to study stem cell engraftment in the absence of alloreactivity. Recently, impaired engraftment was reported in this model and attributed to weak immune reactivity. We have confirmed that there is indeed low-level reactivity mediated by CD8(+) cells and alpha beta-TCR(+) T cells. B6 (CD45.2) recipients were conditioned with total body irradiation (TBI) and transplanted with increasing doses of B6 (CD45.1) bone marrow cells (BMCs). Although chimerism was present at 1 month in all recipients, durable engraftment did not occur with <150 cGy of TBI, emphasizing the importance of long-term follow-up in evaluating nonmyeloablative conditioning approaches. A single dose of cyclophosphamide on day 2 also significantly enhanced engraftment. When B6 TCR beta(-/-), TCR delta(-/-), or TCR beta(-/-)/delta(-/-) (CD45.2) mice were transplanted with CD45.1 bone marrow, significantly enhanced engraftment occurred in recipients lacking alpha beta-TCR(+) T cells (p < .00005). Similarly, removal of alpha beta-TCR(+) host T cells in wild-type recipients resulted in enhanced engraftment. Engraftment was also significantly increased in CD8(-/-) and CD4(-/-)/8(-/-) recipients (p < .0005). Taken together, these results demonstrate that alpha beta-TCR(+) and CD8(+) T cells play a critical role in regulating engraftment of CD45 congenic marrow and suggest that these cells are the main effector cells in low-level alloreactivity to the CD45 disparity.
Similar articles
-
Immunogenicity of Ly5 (CD45)-antigens hampers long-term engraftment following minimal conditioning in a murine bone marrow transplantation model.Stem Cells. 2001;19(1):80-7. doi: 10.1634/stemcells.19-1-80. Stem Cells. 2001. PMID: 11209093
-
Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.Transplantation. 2007 Apr 15;83(7):954-63. doi: 10.1097/01.tp.0000258679.18684.b0. Transplantation. 2007. PMID: 17460568
-
Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.Exp Hematol. 2004 Dec;32(12):1246-54. doi: 10.1016/j.exphem.2004.08.008. Exp Hematol. 2004. PMID: 15588949
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
Ex vivo expansion potential of murine hematopoietic stem cells is a rare property only partially predicted by phenotype.Elife. 2024 Mar 6;12:RP91826. doi: 10.7554/eLife.91826. Elife. 2024. PMID: 38446538 Free PMC article.
-
PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue.J Immunol. 2008 Oct 15;181(8):5313-22. doi: 10.4049/jimmunol.181.8.5313. J Immunol. 2008. PMID: 18832687 Free PMC article.
-
Niche recycling through division-independent egress of hematopoietic stem cells.J Exp Med. 2009 Nov 23;206(12):2837-50. doi: 10.1084/jem.20090778. Epub 2009 Nov 2. J Exp Med. 2009. PMID: 19887396 Free PMC article.
-
Boosting Hematopoietic Engraftment after in Utero Transplantation through Vascular Niche Manipulation.Stem Cell Reports. 2016 Jun 14;6(6):957-969. doi: 10.1016/j.stemcr.2016.05.009. Stem Cell Reports. 2016. PMID: 27304918 Free PMC article.
-
Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression.J Clin Invest. 2017 Aug 1;127(8):2904-2915. doi: 10.1172/JCI75005. Epub 2017 Jun 26. J Clin Invest. 2017. PMID: 28650342 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous